Mimetogen Pharmaceuticals Announces Expiration of Exclusive Option Agreement with Bausch + Lomb

MONTREAL--()--Mimetogen Pharmaceuticals today announced that effective August 31st, 2014, the exclusive option agreement to license an investigational compound in development for the treatment of dry eye syndrome with Bausch + Lomb, has terminated.

About Dry Eye

Dry eye occurs when the eye does not produce enough tears, or when the tears are not of the correct consistency and evaporate too quickly. Inflammation of the surface of the eye may also occur. If left untreated, the condition can lead to pain, ulcers, or scars on the cornea, and some loss of vision, although permanent loss of vision from dry eye is uncommon. Dry eye can also have a significant impact on quality of life, making it more difficult to perform activities such as using a computer or reading for an extended period of time.

About Mimetogen Pharmaceuticals

Mimetogen Pharmaceuticals, Inc.is a private company focused on developing the use of peptidomimetics as a novel approach to treating ophthalmic diseases with high unmet medical needs. The underlying technology was developed at McGill University and the Lady Davis Institute for Medical Research in Montreal. The company is currently developing novel therapeutic approaches for indications including dry eye disease, glaucoma and other degenerative diseases of the retina.

Contacts

Mimetogen Pharmaceuticals Inc.
Garth Cumberlidge, (514) 667-5869

Contacts

Mimetogen Pharmaceuticals Inc.
Garth Cumberlidge, (514) 667-5869